Homepage Top Section2

The collaboration aims to bridge gaps between data generation and actionable insights in spatial proteomics, as multiplex technologies for imaging advance. Spatial proteomics platforms create intricate tissue data,

The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main

The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. FSGS is

The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial,

The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of $250m in

MineBio will supply RoosterBio’s complete platform of products, having already obtained import clearance. This facilitates prompt fulfilment of orders for both research and clinical-grade media solutions focused on

The funding will be used for commercial readiness and the potential US launch of the company’s lead product candidate, AD109, pending approval by the US Food and Drug

The project will enhance Aspect Biosystems’ clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines. The investment is in addition to the

This follows the company’s signing of a definitive agreement in October 2025 to acquire the business. The deal adds advanced Protein A chromatography capabilities and Amsphere Protein A